Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LO LOESTRIN FE vs DEMULEN 1/50-21
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol and norethindrone acetate suppresses gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary, thereby inhibiting ovulation. The progestin component thickens cervical mucus, impeding sperm penetration, and alters endometrial receptivity. Ferrous fumarate provides supplemental iron.
DEMULEN 1/50-21 is a combined oral contraceptive containing ethinyl estradiol and ethynodiol diacetate. Ethinyl estradiol and progestins inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation. Progestins also increase cervical mucus viscosity and alter endometrial receptivity, impeding sperm penetration and implantation.
Oral contraception,Treatment of heavy menstrual bleeding (off-label),Dysmenorrhea (off-label),Acne vulgaris (off-label),Polycystic ovary syndrome (off-label)
Prevention of pregnancy,Treatment of moderate acne vulgaris (off-label use)
One tablet orally once daily. Each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 10 mcg (24 active tablets) followed by ferrous fumarate 75 mg (2 inactive tablets).
1 tablet (ethinyl estradiol 50 mcg, norethindrone 1 mg) orally once daily for 21 days, followed by 7 days off.
Norethindrone: ~8 hours (range 5–12 h); Ethinyl estradiol: ~14 hours (range 10–20 h). Terminal half-life supports once-daily dosing with steady-state reached within 7–14 days.
Ethinylestradiol: 13 ± 3 h (biphasic; terminal phase used for dosing interval). Clinical context: steady-state achieved after ~3 days; missed dose may reduce contraceptive efficacy if >36 h.
Ethinyl estradiol is metabolized primarily via CYP3A4, with hydroxylation and conjugation pathways. Norethindrone acetate is rapidly hydrolyzed to norethindrone, which is metabolized via reduction and conjugation. Ferrous fumarate is absorbed and utilized for hemoglobin synthesis.
Ethinyl estradiol undergoes first-pass metabolism in the gut wall and liver, with hydroxylation by CYP3A4 and conjugation via glucuronidation and sulfation. Ethynodiol diacetate is rapidly deacetylated to norethindrone, which is metabolized by reduction and conjugation, with CYP3A4 as a minor pathway.
Renal (primarily as glucuronide conjugates of norethindrone and ethinyl estradiol): ~40% norethindrone metabolites, ~30% ethinyl estradiol metabolites; Fecal: ~30% norethindrone metabolites, ~40% ethinyl estradiol metabolites.
Renal (approx. 50% as metabolites, <1% unchanged), fecal (approx. 40%, largely as ethinylestradiol conjugates), biliary (minor, enterohepatic recirculation of ethinylestradiol)
Norethindrone: ~61% bound (primarily to albumin and SHBG); Ethinyl estradiol: ~97–98% bound (primarily to albumin, with ~1–2% free).
Ethinylestradiol: 97-98% bound to serum albumin (primarily) and SHBG; ethynodiol diacetate: >95% bound to albumin and SHBG.
Norethindrone: ~4 L/kg; Ethinyl estradiol: ~3–4 L/kg. Indicates extensive tissue distribution consistent with lipophilic steroids.
Ethinylestradiol: 2.8-4.3 L/kg (extensive tissue distribution, including breast and reproductive tissues); ethynodiol: 1.5-2.0 L/kg.
Norethindrone: ~64% (oral); Ethinyl estradiol: ~45% (oral) due to first-pass metabolism, with high interindividual variability.
Oral: Ethinylestradiol 38-48% (first-pass metabolism); ethynodiol diacetate ~60% (rapid hydrolysis to active norethindrone).
No specific dosage adjustment required for renal impairment. Use with caution in patients with renal dysfunction due to potential fluid retention.
No dose adjustment required for mild-moderate renal impairment. Avoid use in severe renal impairment or dialysis due to potential fluid retention and electrolyte disturbances.
Contraindicated in patients with hepatic impairment, including acute or chronic liver disease, hepatic adenomas, or impaired liver function. No adjustment guidelines available; do not use.
Contraindicated in acute or chronic hepatic dysfunction, including Child-Pugh class A, B, or C. Use in mild hepatic impairment not recommended.
Not indicated for use before menarche. For post-menarchal adolescents, same dosing as adults: one tablet orally once daily.
Not indicated for use before menarche. For post-menarcheal adolescents, same dosing as adults. Safety and efficacy established in post-pubertal females.
Not indicated for use in postmenopausal women. No specific dosing adjustments for elderly patients as the drug is not used in this population.
Not indicated after menopause. Risk of thromboembolic events outweighs benefits in women over 35 who smoke or have cardiovascular risk factors.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Cigarette smoking increases the risk of serious cardiovascular events from oral contraceptive use. This risk increases with age and with the number of cigarettes smoked, and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.
Increased risk of venous thromboembolism (VTE), myocardial infarction, and stroke, especially in smokers and women with hypertension or migraines,Adverse effects on bone density and potential for fractures with long-term use,Hepatic adenoma or hepatocellular carcinoma risk,Gallbladder disease,Glucose intolerance and insulin resistance,Elevated blood pressure,Cholestatic jaundice,Ocular lesions (e.g., retinal thrombosis),Depression,Iron overload in patients with hemochromatosis or chronic hemolytic anemia (due to ferrous fumarate)
Increased risk of thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking increases cardiovascular risk, especially in women over 35,Increased risk of hypertension, gallbladder disease, and hepatic neoplasia,Risk of retinal thrombosis; discontinue if unexplained vision loss occurs,May cause fluid retention; use with caution in conditions affected by fluid retention,May induce cholestatic jaundice; discontinue if jaundice develops,May cause carbohydrate and lipid metabolism changes
Current or history of thrombophlebitis, DVT, or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected pregnancy,Undiagnosed abnormal uterine bleeding,Breast carcinoma or other hormone-sensitive cancer,Hepatic tumor (benign or malignant) or active liver disease,Hypersensitivity to any component,Smoking in women over 35,Hemochromatosis or chronic hemolytic anemia (due to ferrous fumarate)
Known or suspected pregnancy,Current or past history of thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Endometrial carcinoma or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma,Active liver disease (e.g., acute viral hepatitis, decompensated cirrhosis),Hypersensitivity to any component
No specific food interactions are known for Lo Loestrin Fe. However, grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects; it is prudent to advise against excessive grapefruit juice consumption. Iron tablets should be taken with food to reduce gastrointestinal upset; calcium-rich foods or supplements may decrease iron absorption, so separate iron intake from high-calcium meals by at least 2 hours.
No specific food interactions. Oral contraceptives may increase caffeine levels; limit caffeine intake if side effects like jitteriness occur. Grapefruit and grapefruit juice do not significantly affect this medication.
Pregnancy category X. Contraindicated in pregnant women due to risk of fetal harm, including cardiovascular defects and neural tube defects. Use during first trimester associated with oral clefts; second and third trimester use may lead to fetal hyperbilirubinemia and jaundice.
First trimester: Use contraindicated due to increased risk of congenital anomalies, particularly cardiovascular defects and limb reduction defects, associated with sex hormones. Second and third trimesters: Avoid due to risk of fetal harm, including masculinization of female fetus with progestins; also associated with increased risk of neonatal jaundice and liver dysfunction.
Excreted in breast milk in small amounts; no reported adverse effects in infants. M/P ratio for ethinyl estradiol is approximately 0.04. Use with caution, especially during early postpartum period due to potential effects on milk production.
Small amounts of ethinyl estradiol and ethynodiol diacetate are excreted in breast milk. M/P ratio not established. Estrogen-progestin combinations may reduce milk production and alter milk composition; use during breastfeeding is generally not recommended. Consider alternative contraception.
Not applicable; drug is contraindicated in pregnancy. No dose adjustments recommended due to absence of safe therapeutic use.
Not applicable as use is contraindicated during pregnancy. No pharmacokinetic studies have been conducted to recommend dose adjustments.
Lo Loestrin Fe contains norethindrone acetate and ethinyl estradiol (1 mg/10 mcg) as the active hormonal pills, with a low iron (75 mg ferrous fumarate) supplement during the placebo week. It is the lowest-dose combination oral contraceptive available, which may minimize estrogen-related side effects. The regimen is 24 active pills, 2 placebo pills, then 2 iron pills, for a 28-day cycle. Spotting and breakthrough bleeding are common, especially in the first few cycles. It is indicated for contraception and not for emergency contraception. The iron tablets do not replace iron deficiency treatment. Contraindicated in patients with a history of thromboembolic disorders, liver disease, or known/suspected pregnancy.
DEMULEN 1/50-21 is a monophasic oral contraceptive containing ethinyl estradiol 50 mcg and ethynodiol diacetate 1 mg. Use with caution in patients over 35 who smoke due to increased cardiovascular risk. Monitor for breakthrough bleeding, especially in the first three cycles. Consider drug interactions with rifampin, anticonvulsants, and broad-spectrum antibiotics. Administer at the same time daily to maintain efficacy. The 21-day regimen requires a 7-day pill-free interval. Instruct to start on first day of menses or first Sunday after onset.
Take one pill daily at the same time each day, preferably after the evening meal.,The first 24 pills are light blue (hormonal), the next 2 are white (placebo), and the last 2 are brown (iron tablets).,If you miss a dose: take it as soon as remembered, and if more than 12 hours late, use backup contraception for 7 days.,Common side effects: spotting, nausea, breast tenderness, and mood changes; these often improve after 3 months.,If you experience severe abdominal or chest pain, headache, or vision changes, seek medical attention.,Iron pills do not treat anemia; they only supplement daily iron needs.,Report any jaundice, depression, or high blood pressure to your healthcare provider.,Use an additional non-hormonal method if starting for the first time after the 5th day of your period.
Take one tablet daily at the same time, starting on the first day of your menstrual period or the first Sunday after your period begins.,Swallow tablet whole with water, with or without food.,After finishing all 21 tablets, wait 7 days before starting a new pack. You will have a withdrawal bleed during this time.,If you miss a tablet by less than 12 hours, take it immediately. If more than 12 hours, take the missed tablet and use backup contraception for 7 days.,Seek emergency medical care for symptoms of blood clots (sudden severe headache, chest pain, shortness of breath, leg pain/swelling), stroke (sudden numbness/weakness, slurred speech), or liver problems (yellowing skin/eyes, dark urine).,Avoid smoking while taking this medication, especially if over age 35, due to increased risk of cardiovascular events.,Inform your healthcare provider about all other medications (including over-the-counter drugs, herbal supplements like St. John's Wort) as they may reduce contraceptive efficacy.,This medication does not protect against HIV or other sexually transmitted infections.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LO LOESTRIN FE vs DEMULEN 1/50-21, answered by our medical review team.
LO LOESTRIN FE is a Combination Oral Contraceptive that works by Combination of ethinyl estradiol and norethindrone acetate suppresses gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary, thereby inhibiting ovulation. The progestin component thickens cervical mucus, impeding sperm penetration, and alters endometrial receptivity. Ferrous fumarate provides supplemental iron.. DEMULEN 1/50-21 is a Combination Oral Contraceptive that works by DEMULEN 1/50-21 is a combined oral contraceptive containing ethinyl estradiol and ethynodiol diacetate. Ethinyl estradiol and progestins inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation. Progestins also increase cervical mucus viscosity and alter endometrial receptivity, impeding sperm penetration and implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LO LOESTRIN FE and DEMULEN 1/50-21 depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LO LOESTRIN FE is: One tablet orally once daily. Each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 10 mcg (24 active tablets) followed by ferrous fumarate 75 mg (2 inactive tablets).. The standard adult dose of DEMULEN 1/50-21 is: 1 tablet (ethinyl estradiol 50 mcg, norethindrone 1 mg) orally once daily for 21 days, followed by 7 days off.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LO LOESTRIN FE and DEMULEN 1/50-21 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LO LOESTRIN FE is classified as Category C. Pregnancy category X. Contraindicated in pregnant women due to risk of fetal harm, including cardiovascular defects and neural tube defects. Use during first trimester associated w. DEMULEN 1/50-21 is classified as Category C. First trimester: Use contraindicated due to increased risk of congenital anomalies, particularly cardiovascular defects and limb reduction defects, associated with sex hormones. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.